PIONEER 9 was a 52-week, phase 2/3a, randomized, controlled trial to assess the efficacy, dose response, and safety of oral semaglutide monotherapy (3, 7, or 14 mg) compared with placebo and liraglutide 0.9 mg in 243 Japanese patients with type 2 diabetes uncontrolled on diet and exercise or one oral glucose-lowering drug (washed out during run-in) [52]
Ozempic and Wegovy are registered trademarks of Novo Nordisk
The patients were supposed to perform follow-up visits 2 months before hydrotherapy and after 3 and 6 months of hydrotherapy for disease condition analysis by the same dermatologist
Patients using semaglutide can, in some cases, achieve a reduction in body weight of around 10-20% over a year, which is substantial compared to other weight loss medications
Also, the study showed that after 14 days of daily dosing (225 mg per day) there were improvements in reaction time and cognition in healthy young men